Number of qualified people: CDEC discussed the uncertainty in the number of people with reasonably critical to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical industry experts consulted by CADTH indicated that some people who're categorized as owning mild or average disorder might have a serious bleeding phenotype, https://hemgenix39371.ka-blogs.com/88996198/5-simple-techniques-for-hemgenix